Project description
Finding the 'switches' to fine-tune macrophage phenotypes in inflammatory diseases
The immune system has many soldiers to fight its battles against invaders. Among them are macrophages, a type of white blood cell that responds to an infection or to an accumulation of damaged or dead cells. As their name suggests, they are large cells that 'eat' their targets and can start an immune response when it 'sees' an infection. Inflammation is vital to the immune system's response to injury and infection, however, these properties can turn against the body in diseases such as atherosclerosis and sepsis. The EU-funded MacrophageEGR project is investigating two different transcriptional regulators whose activation by pro- or anti-inflammatory signals either enhances or represses macrophage activation. By targeting these transcriptional regulators, it may be possible to prevent macrophages from developing phenotypes favouring inflammatory diseases.
Objective
Macrophages play important roles in many aspects of immunity and therefore contribute to a diverse range of human inflammatory diseases, including atherosclerosis. The expression of macrophage genes is tightly controlled by regulatory DNA elements, such as enhancers. When macrophages are exposed to external stimuli, specific transcription factors affect enhancer activity, thereby impacting macrophage function in health and disease.
I am investigating macrophage enhancer activation by interleukin-4 (IL-4). IL-4 is an important anti-inflammatory cytokine that suppresses macrophage activation and regulates immune responses during parasitic infections and allergies. I discovered that IL-4 activates the transcription factor Egr2 leading to specific IL-4-induced enhancer activation in macrophages. I surprisingly noticed that Egr1, while binding highly similar DNA motifs as Egr2, actually represses enhancer activity when macrophages are exposed to pro-inflammatory stimuli, indicating antagonistic effects of Egr1 and Egr2. By targeting transcriptional regulators, macrophages can be skewed to disease-favorable phenotypes. I here propose to investigate and target Egr1 and Egr2 in pro- and anti-inflammatory macrophage phenotypes in vitro and in disease.
Aim 1: To elucidate the molecular mechanism resulting in differential outputs of Egr1 and Egr2 binding, I will study the transcription factor complexes in which Egr1/Egr2 function.
Aim 2: To characterize the function of Egr1 and Egr2 in macrophages, I will study the effects of Egr1/Egr2 deletion in mouse and human macrophages.
Aim 3: To study the roles of Egr1 and Egr2 in macrophage-driven diseases, I will delete Egr1/Egr2 in macrophages and assess the effect of deletion on atherosclerosis and endotoxemia.
My proposed studies will reveal the role of macrophage Egr1 and Egr2 in disease and contribute to increased knowledge on how disease-associated signals regulate enhancer activity in disease-relevant cell types.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health scienceshealth sciencesinflammatory diseases
- natural sciencesbiological sciencesgeneticsDNA
- medical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesclinical medicineallergology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Funding Scheme
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinator
1081 HV Amsterdam
Netherlands